DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Brimonidine (Brimonidine Tartrate Ophthalmic) - Published Studies


Brimonidine Related Published Studies

Well-designed clinical trials related to Brimonidine (Ophthalmic)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. [2014]

Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. [2014]

Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. [2013]

Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial. [2013]

Progesterone increases resistance of ophthalmic and central retinal arteries in climacteric women. [2013]

Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease. [2012]

Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring. [2011.06]

A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. [2011.04]

Effect of a fixed brimonidine-timolol combination on intraocular pressure after phacoemulsification. [2011.02]

Effect of prophylactic topical brimonidine (0.15%) administration on the development of subconjunctival hemorrhage after intravitreal injection. [2011.02]

Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy. [2011.01]

Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. [2011]

[Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension]. [Article in Japanese] [2011]

Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. [2011]

Efficacy of brimonidine in preventing intraocular pressure spikes following phacoemulsification in glaucoma patients. [2010.11]

Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium-aluminum-garnet laser posterior capsulotomy. [2010.10]

Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol. [2010.07]

Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. [2010.04]

Use of brimonidine before LASIK with femtosecond laser-created flaps for the correction of myopia: a contralateral eye study. [2010.01]

Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. [2010]

Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. [2010]

Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. [2010]

Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). [2010]

Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. [2009.09]

The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial. [2009.09]

Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components. [2008.11]

Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2008.07.08]

Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. [2008.04]

Cyclosporine 0.05% ophthalmic preparation to aid recovery from loss of corneal sensitivity after LASIK. [2008.04]

Ocular Penetration and Pharmacokinetics of Topical Gatifloxacin 0.3% and Moxifloxacin 0.5% Ophthalmic Solutions After Keratoplasty. [2008.04]

Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2%pirenzepineophthalmicgelinchildrenwithmyopia. [2008.03.21]

Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. [2008.02]

Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats. [2008.02]

Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes. [2008.01]

Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. [2007.12]

The systemic safety of bromfenac ophthalmic solution 0.09%. [2007.12]

The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. [2007.12]

Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. [2007.11]

Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). [2007.11]

Effect of brimonidine tartrate 0.15% on scotopic pupil: controlled trial. [2007.10]

Effect of Brimonidine Tartrate 0.15% on Scotopic Pupil-Controlled Trial. [2007.09.27]

Effect of prophylactic brimonidine instillation on bleeding during strabismus surgery in adults. [2007.09]

Effects of topical clonidine versus brimonidine on choroidal blood flow and intraocular pressure during squatting. [2007.09]

Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. [2007.09]

Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. [2007.07]

Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. [2007.07]

Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. [2007.04]

Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. [2007.01]

Efficacy of topical ophthalmic prophylaxis in prevention of ophthalmia neonatorum. [2007.01]

Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery. [2007.01]

[Comparative clinical study of two dexamethasone phosphate-containing ophthalmics] [2007]

Does cerebral monitoring improve ophthalmic surgical operating conditions during propofol-induced sedation? [2006.11]

Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. [2006.09]

Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. [2006.09]

The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. [2006.08]

Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. [2006.08]

Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy. [2006.06]

Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis. [2006.06]

Pharmacodynamics of a new ophthalmic mydriatic insert in healthy volunteers: potential alternative as drug delivery system prior to cataract surgery. [2006.06]

A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. [2006.05]

Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. [2006.05]

A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. [2006.04]

Comparative analysis of the effects of brimonidine and dorzolamide on ocular blood flow velocity in patients with newly diagnosed primary open-angle glaucoma. [2006.04]

Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial. [2006.04]

Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients. [2006.03]

Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension. [2006]

Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study. [2005.12]

Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. [2005.12]

Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. [2005.11]

[Lavasept as an alternative to PVP-iodine as a preoperative antiseptic in ophthalmic surgery. Randomized, controlled, prospective double-blind trial] [2005.11]

Advantage of three dimensional animated teaching over traditional surgical videos for teaching ophthalmic surgery: a randomised study. [2005.11]

Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. [2005.11]

Advancing ophthalmic nursing practice through action research. [2005.11]

Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. [2005.11]

The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. [2005.11]

Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. [2005.10]

A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. [2005.10]

Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery. [2005.09]

12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. [2005.09]

Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization. [2005.09]

Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. [2005.09]

Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. [2005.08]

Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. [2005.08]

Comparative evaluation of efficacy and safety of ophthalmic viscosurgical devices in phacoemulsification [ISRCTN34957881]. [2005.07.15]

Brimonidine versus dapiprazole: Influence on pupil size at various illumination levels. [2005.07]

The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. [2005.07]

Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. [2005.07]

A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. [2005.06]

Effectiveness of combined antibiotic ophthalmic solution in the treatment of hordeolum after incision and curettage: a randomized, placebo-controlled trial: a pilot study. [2005.05]

A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. [2005.05]

Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. [2005.05]

Changes in bacterial and fungal ocular flora of clinically normal horses following experimental application of topical antimicrobial or antimicrobial-corticosteroid ophthalmic preparations. [2005.05]

24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. [2005.04]

Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. [2005.04]

Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG). [2005.04]

Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy. [2005.03]

Effect of prophylactic brimonidine on bleeding complications after cataract surgery. [2005.03]

Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A Ofteno and Modusik-A Ofteno. [2005.03]

Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. [2005.02]

Evaluation of a new preoperative ophthalmic solution. [2005.02]

Effects of a 0.9% sodium chloride ophthalmic solution on the ocular surface of symptomatic contact lens wearers. [2005.02]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017